Skip to main content
. 2019 May 8;9:357. doi: 10.3389/fonc.2019.00357

Figure 2.

Figure 2

Mutations of PTEN are not associated with ccRCC prognosis and drug selection. (A) Correlation between the PTEN mutation and mRNA expression. (B,C) Kaplan–Meier survival and disease recurrence curves for renal clear cell carcinoma patients stratified by the PTEN mutation. (D,E) Scattered plot and volcano plot show that multiple cancer cell types with the PTEN mutation were significantly inhibited by GSK690693. (F) Reproduction of the GDSC database by excluding cancer of other types showed that RCC cells with the PTEN mutation was also significantly inhibited by GSK690693. *P < 0.05, ***P < 0.001.